Abemaciclib
- Generic Name
- Abemaciclib
- Brand Names
- Verzenio, Verzenios
- Drug Type
- Small Molecule
- Chemical Formula
- C27H32F2N8
- CAS Number
- 1231929-97-7
- Unique Ingredient Identifier
- 60UAB198HK
- Background
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative a...
- Indication
适应症为:⑴单药治疗接受过内分泌疗法和化疗后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑵或联合氟维司群，二线治疗接受过内分泌疗法后疾病进展的 ER+/HER2-晚期或转移性乳腺癌；⑶联合芳香酶抑制剂作为 ER+/HER2-绝经后女性晚期或转移性乳腺癌的初始内分泌疗法。
- Associated Conditions
- HR+, HER2-, Advanced Breast Cancer, Early Hormone Receptor Positive, HER2/Neu Negative Node Positive Breast Cancer, Metastatic HR + HER2 - breast cancer
- Associated Therapies
- -
ABEMA Alone or in COMBO With MK-6482
- Conditions
- Interventions
- First Posted Date
- 2020-11-13
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT04627064
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
- Conditions
- Metastatic Colon AdenocarcinomaStage IIIA Colon Cancer AJCC v8Stage IIIB Colorectal Cancer AJCC v8Stage IVC Colon Cancer AJCC v8Recurrent Colorectal CarcinomaStage III Colon Cancer AJCC v8Stage III Colorectal Cancer AJCC v8Stage IIIA Rectal Cancer AJCC v8Stage IIIB Colon Cancer AJCC v8Stage IIIC Colorectal Cancer AJCC v8
- Interventions
- First Posted Date
- 2020-11-04
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 46
- Registration Number
- NCT04616183
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT04614194
- Locations
- 🇺🇸
Parkland Hospital, Dallas, Texas, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
ABemaciclib, ET ± paclItaxel in aGgressive HR+/HER2- MBC trIaL
- Conditions
- Interventions
- First Posted Date
- 2020-10-26
- Last Posted Date
- 2024-07-05
- Lead Sponsor
- MedSIR
- Target Recruit Count
- 162
- Registration Number
- NCT04603183
- Locations
- 🇪🇸
Hospital Clinico Universitario de Valencia, Valencia, Spain
🇮🇹Instituto Europeo di Oncologia, Milano, Italy
🇮🇹Azienda Ospedaliero-Universitaria Cittá de la Salute e della Scienza, Torino, Italy
Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-10-18
- Lead Sponsor
- Emory University
- Registration Number
- NCT04585724
PreOperative Endocrine Therapy for Individualised Care With Abemaciclib
- Conditions
- Interventions
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 2032
- Registration Number
- NCT04584853
- Locations
- 🇬🇧
Royal Surrey County Hospital, Guildford, Surrey, United Kingdom
🇬🇧Queen Elizabeth Hospital, King's Lynn, England, United Kingdom
🇬🇧Royal Devon & Exeter Hospital, Exeter, Devon, United Kingdom
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-09-17
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 9
- Registration Number
- NCT04552769
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance
- First Posted Date
- 2020-09-11
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 18
- Registration Number
- NCT04545710
- Locations
- 🇺🇸
UCSD Moores Cancer Center, La Jolla, California, United States
A Basket Trial of an ERK1/2 Inhibitor (LY3214996) in Combination With Abemaciclib.
- Conditions
- Interventions
- First Posted Date
- 2020-09-01
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Anita Turk
- Target Recruit Count
- 16
- Registration Number
- NCT04534283
- Locations
- 🇺🇸
Indiana University Hospital / IU Simon Cancer Center, Indianapolis, Indiana, United States
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
- First Posted Date
- 2020-08-24
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 66
- Registration Number
- NCT04523857
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.